What is Ocugen Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ocugen's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ocugen's Operating Income for the
three
months ended in Mar. 2024 was $ -12.22 Mil. Ocugen's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
GuruFocus does not calculate Ocugen's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Ocugen Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocugen (NAS:OCGN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Ocugen's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-12.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $4.95 Mil.
Ocugen's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| GuruFocus does not calculate Ocugen's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Ocugen Inc has enough cash to cover all of its debt. Its financial situation is stable.
Ocugen (Ocugen) Business Description
Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Executives
| Junge Zhang |
director |
5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
| Quan Anh Vu |
officer: CFO/CBO |
22616 ERWIN STREET, WOODLAND HILLS CA 91367 |
| Shankar Musunuri |
director, officer: Chief Executive Officer |
5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
| Arun Upadhyay |
officer: Chief Scientific Officer |
C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355 |
| Ramesh Kumar |
director |
375 PHEASANT RUN, NEWTOWN PA 18940 |
| Kirsten Castillo |
director |
5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
| Uday Kompella |
director |
5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
| Prabhavathi Fernandes |
director |
114 MILTON AVENUE, CHAPEL HILL NC 27514 |
| Marna C Whittington |
director |
2959 BARLEY MILL ROAD, YORKLYN DE 19736 |
| Jessica Crespo |
officer: CAO/SVP, Finance |
C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355 |
| Sanjay Subramanian |
officer: Chief Financial Officer |
5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
| Manish Potti |
director |
C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355 |
| Vijay Tammara |
officer: Vice President |
5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
| Suha Taspolatoglu |
director |
5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
| Kelly Beck |
officer: Vice President |
5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Ocugen (Ocugen) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCGN has been successfully added to your 